PetLife Pharmaceuticals Seeks Financing for FDA Application

Pharmaceutical Investing

PetLife Pharmaceuticals is pursuing firm Carter, Terry & Company for $4 million which would fund the company’s FDA application of cancer treatments in pets.

PetLife Pharmaceuticals (OTCQB:PTLF) is pursuing investment, asset, and banking service firm Carter, Terry & Company for $4 million which would fund the company’s FDA application of cancer treatments in pets.
As quoted in the press release:

“The funds raised will significantly progress the Company toward bringing VitalZul™ to our customers, the families of pets with cancer,” said Dr. Ralph Salvagno, CEO of PetLife Pharmaceuticals. “Our Company is at the forefront of the fight against cancer in pets, and this round of fundraising is a vote of confidence in our product and company vision.”

Click here to read the full press release.

cancer cancer treatments fda vision Pharmaceutical Investing